Trademark Search in Canada

FREELINE

View On IC.GC.CA

REGISTERED

on 8 Feb 2023

Last Applicant/ Owned by

FREELINE THERAPEUTICS LIMITED

Stevenage Bioscience CatalystGunnels Wood RoadStevenageHerts, SG1 2FX

Serial Number

1931194 filed on 19^th Nov 2018

Registration Number

TMA1165057 registered on 8^th Feb 2023

Registration expiry Date

8^th Feb 2033

Correspondent Address

MCMILLAN LLP

BROOKFIELD PLACE, SUITE 4400BAY WELLINGTON TOWER181 BAY STREETTORONTO

ONTARIO

M5J2T3

FREELINE

Trademark usage description

pharmaceutical, medical and veterinary preparations for prevention, amelioration and treatment of disorders, namely blood disorders, lysosomal storage Read More

Classification Information

Class [005]
Pharmaceutical, medical and veterinary preparations for prevention, amelioration and treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, namely diabetes, Hurler syndrome, Niemann-Pick disease, Tay-Sachs disease, Gaucher disease, Fabry disease, Krabbe disease, Phenylketonuria, Friedreich ataxia, Zellweger syndrome, Adrenoleukodystrophy, Wilson disease and Hemochromatosis, inflammatory disorders, namely C3 glomerulopathy, IgA nephropathy, lupus nephritis, systemic lupus erythematosus, membranous nephropathy, membranoproliferative glomerulonephritis, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, autoimmune haemolytic anemia, ANCA-associated vasculitis, peritonitis, age-related macular degeneration, diabetic retinopathy, dense deposit disease, autoimmune arthritis, rheumatoid arthritis, atherosclerosis, chronic cardiovascular disease, Alzheimer's disease, systemic vasculitis, Guillain-Barre syndrome, and Henoch-Schonlein purpura and immune system disorders, autoimmune disorders, hepatological disorders, peripheral nervous system disorders and central nervous system disorders, namely diseases of the brain, diseases of the spinal cord, Gaucher disease type 2, Gaucher disease type 3, neurodegenerative diseases namely dementia, Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), ocular and ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular and vascular disorders, endocrine disorders, gastrointestinal disorders, dermatological disorders and diseases namely, dermatitis, eczema and psoriasis, acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata, respiratory disorders, urological disorders, cancers and infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic and prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, namely diabetes, Hurler syndrome, Niemann-Pick disease, Tay-Sachs disease, Gaucher disease, Fabry disease, Krabbe disease, Phenylketonuria, Friedreich ataxia, Zellweger syndrome, Adrenoleukodystrophy, Wilson disease and Hemochromatosis, inflammatory disorders, namely C3 glomerulopathy, IgA nephropathy, lupus nephritis, systemic lupus erythematosus, membranous nephropathy, membranoproliferative glomerulonephritis, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, autoimmune haemolytic anemia, ANCA-associated vasculitis, peritonitis, agerelated macular degeneration, diabetic retinopathy, dense deposit disease, autoimmune arthritis, rheumatoid arthritis, atherosclerosis, chronic cardiovascular disease, Alzheimer's disease, systemic vasculitis, Guillain- Barre syndrome, and Henoch-Schonlein purpura and immune system disorders, autoimmune disorders, hepatological disorders, peripheral nervous system disorders and central nervous system disorders, namely diseases of the brain, diseases of the spinal cord, Gaucher disease type 2, Gaucher disease type 3, neurodegenerative diseases namely dementia, Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), ocular and ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular and vascular disorders, endocrine disorders, gastrointestinal disorders, dermatological disorders and diseases namely, dermatitis, eczema and psoriasis, acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata, respiratory disorders, urological disorders, cancers and infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of genetic and inherited and non-infectious diseases and disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, namely diabetes, Hurler syndrome, Niemann-Pick disease, Tay-Sachs disease, Gaucher disease, Fabry disease, Krabbe disease, Phenylketonuria, Friedreich ataxia, Zellweger syndrome, Adrenoleukodystrophy, Wilson disease and Hemochromatosis, inflammatory disorders, namely C3 glomerulopathy, IgA nephropathy, lupus nephritis, systemic lupus erythematosus, membranous nephropathy, membranoproliferative glomerulonephritis, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, autoimmune haemolytic anemia, ANCA-associated vasculitis, peritonitis, age-related macular degeneration, diabetic retinopathy, dense deposit disease, autoimmune arthritis, rheumatoid arthritis, atherosclerosis, chronic cardiovascular disease, Alzheimer's disease, systemic vasculitis, Guillain-Barre syndrome, and Henoch-Schonlein purpura and immune system disorders, autoimmune disorders, hepatological disorders, peripheral nervous system disorders and central nervous system disorders, namely diseases of the brain, diseases of the spinal cord, Gaucher disease type 2, Gaucher disease type 3, neurodegenerative diseases namely dementia, Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), ocular and ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular and vascular disorders, endocrine disorders, gastrointestinal disorders, dermatological disorders and diseases namely, dermatitis, eczema and psoriasis, acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata, respiratory disorders, urological disorders and cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration and prophylaxis of chronic and systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, namely diabetes, Hurler syndrome, Niemann-Pick disease, Tay-Sachs disease, Gaucher disease, Fabry disease, Krabbe disease, Phenylketonuria, Friedreich ataxia, Zellweger syndrome, Adrenoleukodystrophy, Wilson disease and Hemochromatosis, inflammatory disorders, namely C3 glomerulopathy, IgA nephropathy, lupus nephritis, systemic lupus erythematosus, membranous nephropathy, membranoproliferative glomerulonephritis, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, autoimmune haemolytic anemia, ANCA-associated vasculitis, peritonitis, age-related macular degeneration, diabetic retinopathy, dense deposit disease, autoimmune arthritis, rheumatoid arthritis, atherosclerosis, chronic cardiovascular disease, Alzheimer's disease, systemic vasculitis, Guillain-Barre syndrome, and Henoch-Schonlein purpura and immune system disorders, autoimmune disorders, hepatological disorders, peripheral nervous system disorders and central nervous system disorders, namely diseases of the brain, diseases of the spinal cord, Gaucher disease type 2, Gaucher disease type 3, neurodegenerative diseases namely dementia, Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), ocular and ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular and vascular disorders, endocrine disorders, gastrointestinal disorders, dermatological disorders and diseases namely, dermatitis, eczema and psoriasis, acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata, respiratory disorders, urological disorders and cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration and prophylaxis of blood disorders, lysosomal storage disorders, metabolic disorders, namely diabetes, Hurler syndrome, Niemann-Pick disease, Tay-Sachs disease, Gaucher disease, Fabry disease, Krabbe disease, Phenylketonuria, Friedreich ataxia, Zellweger syndrome, Adrenoleukodystrophy, Wilson disease and Hemochromatosis, inflammatory disorders, namely C3 glomerulopathy, IgA nephropathy, lupus nephritis, systemic lupus erythematosus, membranous nephropathy, membranoproliferative glomerulonephritis, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, autoimmune haemolytic anemia, ANCA-associated vasculitis, peritonitis, age-related macular degeneration, diabetic retinopathy, dense deposit disease, autoimmune arthritis, rheumatoid arthritis, atherosclerosis, chronic cardiovascular disease, Alzheimer's disease, systemic vasculitis, Guillain-Barre syndrome, and Henoch-Schonlein purpura and immune system disorders, hepatological disorders, peripheral nervous system disorders and central nervous system disorders, namely diseases of the brain, diseases of the spinal cord, Gaucher disease type 2, Gaucher disease type 3, neurodegenerative diseases namely dementia, Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS); pharmaceutical, medical and clinical preparations for use in gene therapy; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines, namely chemicals, compounds and compositions used to cure, halt and prevent genetic-based disease and illness and to ease symptoms and to help in the diagnosis of genetic-based diseases and illnesses, by modifying gene expression to correct and compensate for an abnormal phenotype, namely for use for prevention, amelioration and treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, namely diabetes, Hurler syndrome, Niemann-Pick disease, Tay-Sachs disease, Gaucher disease, Fabry disease, Krabbe disease, Phenylketonuria, Friedreich ataxia, Zellweger syndrome, Adrenoleukodystrophy, Wilson disease and Hemochromatosis, inflammatory disorders, namely C3 glomerulopathy, IgA nephropathy, lupus nephritis, systemic lupus erythematosus, membranous nephropathy, membranoproliferative glomerulonephritis, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, autoimmune haemolytic anemia, ANCA-associated vasculitis, peritonitis, age-related macular degeneration, diabetic retinopathy, dense deposit disease, autoimmune arthritis, rheumatoid arthritis, atherosclerosis, chronic cardiovascular disease, Alzheimer's disease, systemic vasculitis, Guillain-Barre syndrome, and Henoch-Schonlein purpura and immune system disorders, autoimmune disorders, hepatological disorders, peripheral nervous system disorders and central nervous system disorders, namely diseases of the brain, diseases of the spinal cord, Gaucher disease type 2, Gaucher disease type 3, neurodegenerative diseases namely dementia, Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS) , ocular and ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular and vascular disorders, endocrine disorders, gastrointestinal disorders, dermatological disorders and diseases namely, dermatitis, eczema and psoriasis, acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata, respiratory disorders, urological disorders, cancers and infectious disease; gene therapy preparations; preparations for therapeutic delivery of nucleic acids; viral and nucleic acid vector preparations, namely gene-based biological preparations and medical reagents for use in gene delivery, gene transfer, gene regulation and gene modulation for therapeutic, prophylactic and medical purposes; adeno-associated viral gene therapy preparations.

Classification kind code

Class [040]
Pharmaceutical manufacturing and processing to the order and specification of others; biotechnological and biopharmaceutical manufacturing and processing to the order and specification of others; viral vector production to the order and specification of others; gene therapy manufacturing to the order and specification of others; pharmaceutical formulation to the order and specification of others.

Classification kind code

Class [042]
Scientific and technological services, namely, pharmaceutical research and development; biological, medical, preclinical and clinical research and development; genetic engineering, gene editing, namely, the modification of genetic material in a living organism; genetic medicine, gene therapy and genome editing research, development, analytics, clinical trials and consultancy relating thereto; biochemical assay development and performance; diagnostics development and performance, namely development and performance of diagnostics for screening for eligibility for gene therapy and genetic medicine and assessing the efficacy of gene therapy and genetic medicine; biomarker identification, namely, detection and measurement of biological properties and molecules in the body; manufacturing analytics and manufacturing process design, development and optimisation, namely design, scale-up and optimisation of processes for manufacturing gene therapies and genetic medicines and design and development of analytics for assessing the performance characteristics of such processes; hosting a website communicating educational information relating to gene therapy and genetic medicine.

Classification kind code

Class [044]
Medical services and medical analysis services in the field of genetic medicine, inherited diseases, noninfectious diseases and disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, namely diabetes, Hurler syndrome, Niemann-Pick disease, Tay-Sachs disease, Gaucher disease, Fabry disease, Krabbe disease, Phenylketonuria, Friedreich ataxia, Zellweger syndrome, Adrenoleukodystrophy, Wilson disease and Hemochromatosis, inflammatory disorders, namely C3 glomerulopathy, IgA nephropathy, lupus nephritis, systemic lupus erythematosus, membranous nephropathy, membranoproliferative glomerulonephritis, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, autoimmune haemolytic anemia, ANCA-associated vasculitis, peritonitis, age-related macular degeneration, diabetic retinopathy, dense deposit disease, autoimmune arthritis, rheumatoid arthritis, atherosclerosis, chronic cardiovascular disease, Alzheimer's disease, systemic vasculitis, Guillain-Barre syndrome, and Henoch- Schonlein purpura and immune system disorders, autoimmune disorders, hepatological disorders, peripheral nervous system disorders and central nervous system disorders, namely diseases of the brain, diseases of the spinal cord, Gaucher disease type 2, Gaucher disease type 3, neurodegenerative diseases namely dementia, Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS), ocular and ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular and vascular disorders, endocrine disorders, gastrointestinal disorders, dermatological disorders and diseases namely, dermatitis, eczema and psoriasis, acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata, respiratory disorders, and urological disorders, and cancers; medical services in the field of gene therapy and genetic medicine; medical services in the field of gene therapy for blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory and immune system disorders, hepatological disorders, and nervous system disorders; medical services in the field of gene and nucleic acid delivery and modification for therapeutic purposes; gene therapy design and delivery; advisory services relating to gene therapy.

Classification kind code

Mark Details

Serial Number

1931194

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 190 on 4^th Jan 2023	Registration Pending
Submitted for opposition 42 on 12^th Oct 2022	Advertised
Submitted for opposition 27 on 14^th Sept 2022	Approval Notice Sent
Submitted for opposition 26 on 14^th Sept 2022	Approved
Submitted for opposition 15 on 10^th Feb 2022	Correspondence Created
Submitted for opposition 22 on 29^th Jun 2021	Search Recorded
Submitted for opposition 20 on 29^th Jun 2021	Examiner's First Report
Submitted for opposition 31 on 23^rd Nov 2018	Formalized
Submitted for opposition 1 on 20^th Nov 2018	Created
Submitted for opposition 30 on 19^th Nov 2018	Filed